{"id":"W4399517501","doi":"10.1136/ijgc-2024-005588","title":"A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Oncology; Cervical cancer; Internal medicine; Cancer; Urology; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002228779,0.001754662,0.003341034,0.0004427413,0.0004667689,0.001308576,0.00143333,0.002006801,0.01118398],"category_scores_gemma":[0.002255613,0.0008178439,0.002585181,0.0003971551,0.00141831,0.001645464,0.0005661781,0.004243454,0.001927888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008244299,"about_ca_system_score_gemma":0.001242189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009913802,"about_ca_topic_score_gemma":0.002806221,"domain_scores_codex":[0.9991849,0.0004319923,0.00004999143,0.0001648321,0.00005495482,0.0001132732],"domain_scores_gemma":[0.9989673,0.0003582767,0.0001697583,0.0001115566,0.00006808668,0.0003249427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9812433,0.004033463,0.0003764448,0.0004792341,0.001242321,0.00003226552,0.00004058319,0.000249559,0.001842401,0.0001279453,0.000615802,0.009716542],"study_design_scores_gemma":[0.964727,0.03360468,0.0005884456,0.00001274074,0.0003421447,0.00002342907,0.00001890897,0.0001493565,0.0001303508,0.00009634717,0.0002987967,0.000007934546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818564,0.005332016,0.001071604,0.001327184,0.001136196,0.003384711,0.00209672,0.0001959769,0.003599216],"genre_scores_gemma":[0.9778495,0.002988236,0.002615011,0.002745808,0.0005352822,0.003981017,0.002611668,0.00005163913,0.006621756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01118398,"threshold_uncertainty_score":0.03741413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07864419944511089,"score_gpt":0.4285225515594585,"score_spread":0.3498783521143476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}